ARCHIVES

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

This article is from The Cancer Letter archive.

Vol. 35 No. 12 | December 28, 2012

Download PDF Visit The Full Archive

Related Articles

U.S., France Offer Carcinogenesis Program

February 13, 1981

Who Makes This Drug? Secretive Contract Manufacturing Agreements Complicate Solutions to Shortages of Generics

January 3, 2014

Lawyer Says Salick didn’t Anticipate Ouster By Zeneza

May 2, 1997

DCT Advisors Okay Two New RFA Concepts In Clinical Research, Biodiversity Groups

November 8, 1991

BMS, ImClone To Develop New Drug IMC-C225, Targets EGF Receptor.

September 28, 2001

Elevated Baseline Glucose Levels Associated With Higher Cancer Risk

November 25, 2011